Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 03, 2024 08:00 ET | Source: Evaxion Biotech

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through...
February 29, 2024 08:30 ET | Source: Imunon, Inc.

Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5

Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality LAWRENCEVILLE, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE)...
January 26, 2023 07:00 ET | Source: AC Immune SA

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial ACI-24.060 elicited an anti-Abeta antibody response...
June 21, 2022 08:00 ET | Source: Certara

Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics

PRINCETON, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Certara Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of new versions of its Immunogenicity (IG),...
February 23, 2022 16:30 ET | Source: Certara

U.S. FDA Licenses Certara’s Immunogenicity Simulator

PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has licensed...
April 23, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Provides Update on GBM Program and Announces Upcoming Conference Call

10mcg dose selected to advance into Part B of Phase 1/2a study of VBI-1901 in recurrent GBMExpanded data from Part A of the Phase 1/2a study of VBI-1901 selected for poster presentation at...
November 07, 2017 07:30 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update

Patient Data From Ongoing Phase 2 Trial to be Presented Today at the American College of Rheumatology (ACR) 2017 Annual MeetingPreparations for Phase 3 Program UnderwayReceived $7.5 Million From Spark...